Suppr超能文献

急性低氧性呼吸衰竭肺炎患者早期开始高流量鼻导管给氧治疗的效果

Outcome of Early Initiation of High-flow Nasal Oxygen Therapy among Pneumonia Patients Presenting with Acute Hypoxemic Respiratory Failure.

作者信息

Magdy Doaa M

机构信息

Department of Chest Diseases, Assiut University Hospital, Assiut, Egypt.

出版信息

Indian J Crit Care Med. 2024 Aug;28(8):753-759. doi: 10.5005/jp-journals-10071-24769. Epub 2024 Jul 31.

Abstract

BACKGROUND

High-flow nasal oxygen (HFNO) therapy is an upcoming and beneficial modality for patients with acute hypoxemic respiratory failure (AHRF).

OBJECTIVES

To evaluate whether early use of HFNO in pneumonia patients with AHRF can reduce the need for invasive ventilation.

PATIENTS AND METHODS

In this prospective, randomized controlled trial, 160 patients who fulfilled the criteria were included. The patient's characteristics, sequential organ failure assessment score, and simplified acute physiology score were recorded. Respiratory rate (RR), and oxygenation parameters (PaO/FiO), and RR-oxygenation index at selected time intervals were collected and analyzed. The primary outcome was the number of patients who needed intubation. Secondary outcomes included length of intensive care unit (ICU) and hospital stay and mortality at day 28.

RESULTS

The rate of intubation was not statistically significant between the two groups 15 vs 18.7%; difference 3.7% [(95% confidence interval (CI): 2.5-5.7%]. In 48-hour time periods, the mean PaO/FiO ratio was significantly increased in the HFNO group compared with the non-invasive ventilation (NIV) group. The RRs and heart rate (HR) showed a significant decrease in the HFNO group.The length of ICU and hospital stays was not different between both groups. No significant differences were found in mortality rates between the HFNO and NIV groups 9 (11.2%) and 10 (12.5%), with 1.3% (95% CI: 0.7-3.8%) ( = 0.21). Multivariate analysis demonstrated that low baseline PaO/FiO, Respiratory rate-oxygenation index (ROX index) ≤ 5.4 measured at 12 hour and high severity scores were independent risk factors for intubation.

CONCLUSION

Treatment with HFNO did not reduce the need for intubation among patients with pneumonia-induced AHRF, despite the improved PaO/FiO observed with HFNO compared with NIV.

CLINICAL TRIAL NO

NCT05809089.

HOW TO CITE THIS ARTICLE

Magdy DM. Outcome of Early Initiation of High-flow Nasal Oxygen Therapy among Pneumonia Patients Presenting with Acute Hypoxemic Respiratory Failure. Indian J Crit Care Med 2024;28(8):753-759.

摘要

背景

高流量鼻导管给氧(HFNO)治疗是一种新兴的、对急性低氧性呼吸衰竭(AHRF)患者有益的治疗方式。

目的

评估AHRF肺炎患者早期使用HFNO是否能减少有创通气的需求。

患者与方法

在这项前瞻性随机对照试验中,纳入了160例符合标准的患者。记录患者的特征、序贯器官衰竭评估评分和简化急性生理学评分。收集并分析选定时间间隔的呼吸频率(RR)、氧合参数(PaO/FiO)和RR-氧合指数。主要结局是需要插管的患者数量。次要结局包括重症监护病房(ICU)住院时间、住院时间和第28天的死亡率。

结果

两组间插管率无统计学差异(15%对18.7%;差异3.7%[(95%置信区间(CI):2.5-5.7%])。在48小时时间段内,与无创通气(NIV)组相比,HFNO组的平均PaO/FiO比值显著升高。HFNO组的RR和心率(HR)显著降低。两组间ICU住院时间和住院时间无差异。HFNO组和NIV组的死亡率无显著差异(分别为9例(11.​​2%)和10例(12.5%),差异1.3%(95%CI:0.7-3.8%)(P=0.21)。多因素分析表明,低基线PaO/FiO、12小时时测得的呼吸频率-氧合指数(ROX指数)≤5.4以及高严重程度评分是插管的独立危险因素。

结论

尽管与NIV相比,HFNO观察到PaO/FiO有所改善,但HFNO治疗并未降低肺炎诱发的AHRF患者的插管需求。

临床试验编号

NCT05809089。

如何引用本文

Magdy DM。急性低氧性呼吸衰竭肺炎患者早期开始高流量鼻导管给氧治疗的结局。《印度重症医学杂志》2024;28(8):753-759。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验